ScreenerHero

IMNNImunon Inc. Common Stock

NAS · US · Healthcare · Biotechnology · imunon.com
1.640USD+3.80%Mkt Cap: 9.20M $P/E: —

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap9.20M $
Enterprise Value12.10M $
Revenue (TTM)—
Gross Profit-409.92K $
Net Income (TTM)-14.50M $
Revenue/Share—
Last Price1.640 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.89
PEG5.03
EV/EBITDA-0.83
EV/Revenue—
P/S—
P/B3.81
EPS (TTM)-2.89
EPS (Forward)-1.77
52W Range
1.4703% of range6.960
52W High6.960 USD
52W Low1.470 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-205.26%
ROA-117.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.90M $
CapEx (TTM)280.57K $
FCF Margin—
FCF Yield-103.55%
Net Debt980.91K $
Net Debt/EBITDA-0.07
Balance Sheet
Debt/Equity0.14
Current Ratio1.82
Quick Ratio1.44
Book Value/Sh0.4150 USD
Cash/Share1.223 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split115:100
Split DateAug 7, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.00 USD
Upside (mean)+936.6%
Target Range10.00 USD – 25.00 USD
$10.00+936.6% to mean$25.00
# Analysts5
Ownership
Shares Out.5.61M
Float5.31M
Insiders5.14%
Institutions5.68%
Short Interest
Short Ratio0.7d
Short % Float3.60%
Short % Out.3.57%
Shares Short150.20K
Short (prev mo.)50.97K
Technical
SMA 501.755 (-6.6%)
SMA 2002.873 (-42.9%)
Beta1.97
S&P 52W Chg18.16%
Avg Vol (30d)189.70K
Avg Vol (10d)60.30K
Technical Indicators
RSI (14)47.1
MACD-0.0511
MACD Signal-0.0685
MACD Hist.+0.0174
BB Upper1.682 USD
BB Middle1.595 USD
BB Lower1.507 USD
BB Width10.99%
ATR (14)0.1147 USD
Vol Ratio (20d)0.61x